SG11201809041TA - Compositions and methods for selective protein expression - Google Patents

Compositions and methods for selective protein expression


Publication number
SG11201809041TA SG11201809041TA SG11201809041TA SG11201809041TA SG 11201809041T A SG11201809041T A SG 11201809041TA SG 11201809041T A SG11201809041T A SG 11201809041TA SG 11201809041T A SG11201809041T A SG 11201809041TA SG 11201809041T A SG11201809041T A SG 11201809041TA
Prior art keywords
Prior art date
Application number
Andrei Golosov
Carla Guimaraes
Gregory Motz
Michael Milone
Christoph Ellebrecht
Aimee Payne
Original Assignee
Novartis Ag
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201662322931P priority Critical
Priority to US201762481094P priority
Application filed by Novartis Ag, Univ Pennsylvania filed Critical Novartis Ag
Priority to PCT/US2017/027778 priority patent/WO2017181119A2/en
Publication of SG11201809041TA publication Critical patent/SG11201809041TA/en



    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/00Fusion polypeptide
    • C07K2319/95Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization MD 1111101110101011111 HO 11111 011101111110101 0111110111110111 OM International Bureau 0.. .... .. (10) International Publication Number ..... ..or::,,, (43) International Publication Date WO 2017/181119 A2 19 October 2017(19.10.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 14/725 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/US2017/027778 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: 14 April 2017 (14.04.2017) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (25) Filing Language: English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (26) Publication Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (30) Priority Data: ZA, ZM, ZW. 62/322,931 15 April 2016 (15.04.2016) US 62/481,094 3 April 2017 (03.04.2017) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicants: NOVARTIS AG [CH/CH]; Lichstrasse 35, CH-4056 Basel (CH). THE TRUSTEES OF THE UNI- VERSITY OF PENNSYLVANIA [US/US]; 3160 Chest- nut Street, Suite 200, Philadelphia, PA 19104 (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) Inventors; and (71) Applicants (for US only): GOLOSOV, Andrei [ /US]; LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Novartis Institutes for BioMedical Reseach, Inc., 100 GW, KM, ML, MR, NE, SN, TD, TG). Technology Square, Cambridge, MA 02139 (US). Declarations under Rule 4.17: — _ GUIMARAES, Carla [PT/US]; Novartis Institutes for BioMedical Reseach, Inc., 100 Technology Square, Cam- — as to applicant's entitlement to apply for and be granted a _ bridge, MA 02139 (US). MOTZ, Gregory [US/US]; 83 4.17(ii)) patent (Rule Greene St., Quincy, MA 02170 (US). MILONE, Michael — as to the applicant's entitlement to claim the priority of the = [US/US]; 314 Surrey Road, Cherry Hill, NJ 08002 (US). earlier application (Rule 4.17(iii)) — ELLEBRECHT, Christoph, T. [DE/US]; 415 S. 13th Street, Philadelphia, PA 19147 (US). PAYNE, Aimee, S. Published: = — [US/US]; 536 Hamilton Road, Merion Station, PA 19066 — without international search report and to be republished = (US). upon receipt of that report (Rule 48.2(g)) = Agents: COLLAZO, Diana, M. et al.; Lando & Anastasi, LLP, Riverfront Office Park, One Main Street, Suite 1100, (74) — with sequence listing part of description (Rule 5.2(a)) — = Cambridge, MA 02142 (US). — = = = = = = ei C:7 Il Il Il of (54) Title: COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION 1-1 ----- (57) : Provided herein are fusion proteins including two protein domains separated by a heterologous protease cleavage I N I-1 site, wherein a first of the protein domains is a conditional expression domain. Thus, the fusion proteins comprise three essential ele - C ments: a conditional expression domain, a domain containing the protein of interest, and a protease cleavage domain separating the N two. Also provided herein are methods for treating autoantibody and alloantibody-mediated diseases or conditions in a subject by en. ) targeting B cells with anti-B cell modified T cells. In one embodiment, a chimeric antigen receptor (CAR) modified T cell is select- ively ablated in a subject after adoptive transfer. Pharmaceutical compositions comprising the temporally regulated CAR modified T 5 cell are also described herein.
SG11201809041TA 2016-04-15 2017-04-14 Compositions and methods for selective protein expression SG11201809041TA (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US201662322931P true 2016-04-15 2016-04-15
US201762481094P true 2017-04-03 2017-04-03
PCT/US2017/027778 WO2017181119A2 (en) 2016-04-15 2017-04-14 Compositions and methods for selective protein expression

Publications (1)

Publication Number Publication Date
SG11201809041TA true SG11201809041TA (en) 2018-11-29



Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809041TA SG11201809041TA (en) 2016-04-15 2017-04-14 Compositions and methods for selective protein expression

Country Status (10)

Country Link
EP (1) EP3443096A2 (en)
JP (1) JP2019518424A (en)
KR (1) KR20180134385A (en)
CN (1) CN109715808A (en)
AU (1) AU2017250304A1 (en)
BR (1) BR112018071096A2 (en)
CA (1) CA3021027A1 (en)
IL (1) IL262321D0 (en)
SG (1) SG11201809041TA (en)
WO (1) WO2017181119A2 (en)

Family Cites Families (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4433059A (en) 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4851332A (en) 1985-04-01 1989-07-25 Sloan-Kettering Institute For Cancer Research Choriocarcinoma monoclonal antibodies and antibody panels
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
JPH021556A (en) 1988-06-09 1990-01-05 Snow Brand Milk Prod Co Ltd Hybrid antibody and production thereof
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag Bispecific, oligo, mono- and oligovalent antikoerperkonstrukte, their production and use
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
WO1991003493A1 (en) 1989-08-29 1991-03-21 The University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5273743A (en) 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co., Inc. A method for reducing the immunogenicity of antibody variable domains
DE4118120A1 (en) 1991-06-03 1992-12-10 Behringwerke Ag Tetra Valente bispecific receptors, their manufacture and use
US6511663B1 (en) 1991-06-11 2003-01-28 Celltech R&D Limited Tri- and tetra-valent monospecific antigen-binding proteins
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and derivatives chemical immuno including immotoxines
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council Procedures for the production of humanized antibodies.
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
AT249840T (en) 1991-12-13 2003-10-15 Xoma Corp Methods and materials for preparation of modified antibody variable domains and their therapeutic use
HU215180B (en) 1992-01-23 1998-10-28 Merck Patent Gmbh. A process for the preparation of monomeric and dimeric antibody-fragment fusion proteins
DE69334351D1 (en) 1992-02-06 2011-05-12 Novartis Vaccines & Diagnostic Biosynthetic binding protein for tumor markers
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
AT165113T (en) 1992-05-08 1998-05-15 Creative Biomolecules Inc Multivalent chimeric proteins anologe and process for their applications
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
EP1621554B2 (en) 1992-08-21 2012-08-29 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DE69334287D1 (en) 1992-09-25 2009-07-09 Avipep Pty Ltd Target molecules binding polypeptides of an Ig-like domain VL VH to an Ig-like domain consisting bound
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
GB9323648D0 (en) 1992-11-23 1994-01-05 Zeneca Ltd Proteins
JP3720353B2 (en) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル Multivalent and multispecific binding proteins, their preparation and use
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
US5635602A (en) 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5646253A (en) 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
JP3659261B2 (en) 1994-10-20 2005-06-15 モルフォシス・アクチェンゲゼルシャフト Targeting heteroconjugate to multifunctional complex of recombinant proteins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
CA2222055A1 (en) 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
BR9606706A (en) 1995-10-16 1999-04-06 Unilever Nv Analogous bispecific or bivalent antibody fragment using process for producing the same
WO1997024373A1 (en) 1995-12-29 1997-07-10 Medvet Science Pty. Limited Monoclonal antibody antagonists to haemopoietic growth factors
AU703769B2 (en) 1996-01-05 1999-04-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Mesothelium antigen and methods and kits for targeting it
EP0894135B1 (en) 1996-04-04 2004-08-11 Unilever N.V. Multivalent and multispecific antigen-binding protein
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
AU5158098A (en) 1996-10-25 1998-05-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions for inhibiting inflammation and angiogenesis compri sing a mammalian CD97 alpha subunit
AU7266698A (en) 1997-04-30 1998-11-24 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DE69827507T2 (en) 1997-06-11 2006-03-09 Borean Pharma A/S Trimerisierendes module
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
AT461282T (en) 1997-10-27 2010-04-15 Bac Ip Bv Multivalent antigen-binding proteins
DE69833459T2 (en) 1997-12-01 2006-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies, as well fv molecules, immunoconjugates and with high binding affinity for mesothelin and methods for their use
DE69922159T2 (en) 1998-01-23 2005-12-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Multipurpose antibody derivatives
CZ121599A3 (en) 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Single-chain molecule binding several antigens, process of its preparation and medicament in which the molecule is comprised
DE19819846B4 (en) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalent antibody constructs
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
JP2002521053A (en) 1998-07-28 2002-07-16 マイクロメット アーゲー Heteromini body
JP2002535958A (en) 1998-10-19 2002-10-29 アリアド ジーン セラピューティクス インコーポレイテッド Materials and methods relating to conditions set domain
AU1121000A (en) * 1998-10-19 2000-05-08 Ariad Gene Therapeutics, Inc. Materials and methods involving conditional retention domains
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
JP2003516124A (en) 1999-10-15 2003-05-13 カーネギー インスティテューション オブ ワシントン rna interference pathway genes as a means of genetic interference targeting
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US7262005B1 (en) * 2000-02-04 2007-08-28 Aurora Biosciences Corporation Methods of protein destabilization and uses thereof
WO2001062895A2 (en) 2000-02-24 2001-08-30 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
AT510855T (en) 2000-03-06 2011-06-15 Univ Kentucky Res Found Use of an antibody or an immunotoxin that binds selectively to CD123, or the impairment of hematologic cancer progenitor cells
CN1308447C (en) 2000-10-20 2007-04-04 中外制药株式会社 Degraded agonist antibody
HU0300369A2 (en) 2000-04-11 2003-06-28 Genentech, Inc. Multivalent antibodies and their applications
CA2409991A1 (en) 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
CA2410551A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
CA2417185A1 (en) 2000-07-25 2002-01-31 Shui-On Leung Multivalent target binding protein
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
WO2002072635A2 (en) 2001-03-13 2002-09-19 University College London Specific binding members
CN1294148C (en) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 Single-stranded cyctic trispecific antibody
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
DK1419179T3 (en) 2001-08-10 2010-06-21 Univ Aberdeen Antigen binding domains from fish
EP1293514B1 (en) 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimeric single chain tandem Fv-antibodies
WO2003049684A2 (en) 2001-12-07 2003-06-19 Centocor, Inc. Pseudo-antibody constructs
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US20040018557A1 (en) 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US8030461B2 (en) 2002-04-15 2011-10-04 Chugai Seiyaku Kabushiki Kaisha Methods for constructing scDb libraries
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
GB0305702D0 (en) 2003-03-12 2003-04-16 Univ Birmingham Bispecific antibodies
WO2004087758A2 (en) 2003-03-26 2004-10-14 Neopharm, Inc. Il 13 receptor alpha 2 antibody and methods of use
AU2004232928A1 (en) 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
CA2530388A1 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
EP1638510B1 (en) 2003-07-01 2015-09-02 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US7696322B2 (en) 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
EP1651675A1 (en) 2003-08-05 2006-05-03 Morphotek, Inc. A variant cell surface molecule associated with cancer
WO2005042743A2 (en) 2003-08-18 2005-05-12 Medimmune, Inc. Humanization of antibodies
CA2537055A1 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
AU2004308439A1 (en) 2003-12-22 2005-07-14 Centocor, Inc. Methods for generating multimeric molecules
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US8383575B2 (en) 2004-01-30 2013-02-26 Paul Scherrer Institut (DI)barnase-barstar complexes
JP5070045B2 (en) 2004-05-27 2012-11-07 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア New artificial antigen-presenting cells and their applications
JP2008512352A (en) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド The novel tetravalent bispecific antibody
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
WO2006099141A2 (en) 2005-03-10 2006-09-21 Morphotek, Inc. Anti-mesothelin antibodies
TWI544076B (en) 2005-03-31 2016-08-01 Chugai Pharmaceutical Co Ltd
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
EP1874824A4 (en) 2005-04-06 2009-12-30 Ibc Pharmaceuticals Inc Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
JP5838021B2 (en) 2005-04-15 2015-12-24 マクロジェニクス,インコーポレーテッド Covalent diabody and its use
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
EP1726650A1 (en) 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007024715A2 (en) 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
DE602005018477D1 (en) 2005-08-26 2010-02-04 Pls Design Gmbh Bivalent IgY antibody constructs for diagnostic and therapeutic applications
WO2007044887A2 (en) 2005-10-11 2007-04-19 Transtarget, Inc. Method for producing a population of homogenous tetravalent bispecific antibodies
US8623356B2 (en) 2005-11-29 2014-01-07 The University Of Sydney Demibodies: dimerization-activated therapeutic agents
CA2638794A1 (en) 2006-02-15 2007-08-23 Imclone Systems Incorporated Functional antibodies
BRPI0709598A8 (en) 2006-03-17 2019-01-08 Biogen Idec Inc stabilized polypeptide compositions
ES2363891T3 (en) 2006-03-20 2011-08-18 The Regents Of The University Of California Antibodies to the antigen of prostate stem cells (PSCA) genetically modified for targeting to cancer.
AR060070A1 (en) 2006-03-24 2008-05-21 Merck Patent Gmbh heterodimeric protein domains obtained by engineering
WO2007112362A2 (en) 2006-03-24 2007-10-04 The Regents Of The University Of California Construction of a multivalent scfv through alkyne-azide 1,3-dipolar cycloaddition
JP5144499B2 (en) 2006-03-31 2013-02-13 中外製薬株式会社 Antibodies modified method for the purification of bispecific antibody
TWI395754B (en) 2006-04-24 2013-05-11 Amgen Inc Humanized c-kit antibody
ES2469676T3 (en) 2006-05-25 2014-06-18 Bayer Intellectual Property Gmbh Complex molecular dimricos
US20070274985A1 (en) 2006-05-26 2007-11-29 Stefan Dubel Antibody
RU2487888C2 (en) 2006-06-12 2013-07-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Single-chain multivalent binding proteins with effector function
WO2008022349A2 (en) 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
EP2059533B1 (en) 2006-08-30 2012-11-14 Genentech, Inc. Multispecific antibodies
CA2977261A1 (en) 2006-10-04 2008-04-10 Kobenhavns Universitet Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
FR2906808B1 (en) 2006-10-10 2012-10-05 Univ Nantes Using specific monoclonal antibodies of the o-acetylated ganglioside GD2 in the treatment of certain cancers
KR20090105913A (en) 2006-11-02 2009-10-07 다니엘 제이 카폰 Hybrid immunoglobulins with moving parts
US7635753B2 (en) 2007-02-19 2009-12-22 Wisconsin Alumni Research Foundation Prostate cancer and melanoma antigens
JP5681482B2 (en) 2007-03-29 2015-03-11 ゲンマブ エー/エス Bispecific antibodies and a method for manufacturing
US8163279B2 (en) 2007-04-13 2012-04-24 Stemline Therapeutics, Inc. IL3Rα antibody conjugates and uses thereof
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
JP2010190572A (en) 2007-06-01 2010-09-02 Sapporo Medical Univ Antibody directed against il13ra2, and diagnostic/therapeutic agent comprising the antibody
CN101952312A (en) 2007-07-31 2011-01-19 米迪缪尼有限公司 Multispecific epitope binding proteins and uses thereof
EP2532676B1 (en) 2007-08-15 2017-03-22 Bayer Pharma Aktiengesellschaft Protease-regulated antibody
BRPI0816014A8 (en) 2007-10-01 2018-06-19 Squibb Bristol Myers Co monoclonal isolated human antibody, composition, conjugated antibody molecule partner isolated nucleic acid molecule, expression vector, host cell, method for preparing an anti-mesothelin antibody, the growth method of inhibiting a tumor cell expressing mesothelin, method treating cancer in an individual, anti-mesothelin antibody isolated, and methods of inhibiting the growth of a cell expressing mesothelin
EP3103814A1 (en) 2007-11-26 2016-12-14 Bayer Intellectual Property GmbH Anti-mesothelin antibodies and uses therefor
EP2215123A1 (en) 2007-11-27 2010-08-11 Ablynx N.V. Immunoglobulin constructs
EP2641919A3 (en) 2007-11-30 2014-05-07 Glaxo Group Limited Antigen-binding constructs
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
PT2235064E (en) 2008-01-07 2016-03-01 Amgen Inc Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
JP5694923B2 (en) 2009-04-27 2015-04-01 協和発酵キリン株式会社 Anti IL-3Rα antibodies for the purpose of blood tumor therapy
JP2012525149A (en) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド Methods for making heteromultimeric molecules
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
CN105085681B (en) 2009-12-02 2018-12-28 伊麦吉纳博公司 Target the J591 miniantibody and double antibody of human prostate-specific membrane antigen
PT2538976T (en) 2010-02-24 2017-03-08 Immunogen Inc Immunoconjugates against folate receptor 1 and uses thereof
CA2796181A1 (en) 2010-04-20 2011-10-27 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
US9242014B2 (en) 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
AU2011268110B2 (en) 2010-06-19 2016-05-19 Memorial Sloan-Kettering Cancer Center Anti-GD2 antibodies
AU2011281062B2 (en) 2010-07-21 2015-01-22 Board Of Regents, The University Of Texas System Methods and compositions for modification of a HLA locus
EP3467101A3 (en) 2010-09-08 2019-06-19 Baylor College of Medicine Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells
PL3214091T3 (en) 2010-12-09 2019-03-29 The Trustees Of The University Of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN107188969A (en) 2011-04-08 2017-09-22 美国卫生和人力服务部 Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
AR086044A1 (en) 2011-05-12 2013-11-13 Imclone Llc Antibodies that specifically bind to an extracellular domain of c-kit and uses thereof
JP6263467B2 (en) 2011-05-27 2018-01-17 グラクソ グループ リミテッドGlaxo Group Limited Bcma (cd269 / tnfrsf17) binding protein
EP2755487B1 (en) 2011-09-16 2018-12-19 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
EA201490636A1 (en) 2011-09-16 2014-08-29 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания T-cells designed with the help of rna for the treatment of malignous non-formations
ITMO20110270A1 (en) 2011-10-25 2013-04-26 Sara Caldrer A cell effector modified to treat malignancies expressing disialonganglioside gd2
SG11201401422VA (en) 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
WO2013063419A2 (en) 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
US9439768B2 (en) 2011-12-08 2016-09-13 Imds Llc Glenoid vault fixation
JP2015513394A (en) 2012-02-13 2015-05-14 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート Bispecific chimeric antigen receptors and their therapeutic use
MX2014010183A (en) 2012-02-22 2015-03-20 Univ Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer.
EP2828290B1 (en) 2012-03-23 2018-08-15 The United States of America, represented by the Secretary, Department of Health and Human Services Anti-mesothelin chimeric antigen receptors
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
EP2850106A4 (en) 2012-05-18 2016-04-20 Scott&White Healthcare Bispecific scfv immunofusion (bif)
PE03362015A1 (en) 2012-05-25 2015-03-25 Univ California Methods and compositions for modification of target RNA-directed DNA and for modulation of transcription directed RNA
WO2013192294A1 (en) 2012-06-20 2013-12-27 Boston 3T Biotechnologies, Inc. Cellular therapies for treating and preventing cancers and other immune system disorders
WO2014012001A2 (en) * 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Use of cart19 to deplete normal b cells to induce tolerance
JP2015527070A (en) 2012-08-20 2015-09-17 フレッド ハッチンソン キャンサー リサーチ センター Methods and compositions for cellular immunotherapy
EP2904106A4 (en) 2012-10-01 2016-05-11 Univ Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
TW201425336A (en) 2012-12-07 2014-07-01 Amgen Inc BCMA antigen binding proteins
WO2014093635A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CN105658796A (en) 2012-12-12 2016-06-08 布罗德研究所有限公司 CRISPR/CAS component systems, methods and compositions for sequence manipulation
EP2953974B1 (en) 2013-02-05 2017-12-20 EngMab Sàrl Bispecific antibodies against cd3epsilon and bcma
CN105358576A (en) 2013-02-20 2016-02-24 诺华股份有限公司 Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
EP2958942A1 (en) 2013-02-20 2015-12-30 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
WO2014138805A1 (en) 2013-03-14 2014-09-18 Csl Limited Anti il-3r alpha agents and uses thereof
WO2014138819A1 (en) 2013-03-14 2014-09-18 Csl Limited Agents that neutralize il-3 signaling and uses thereof
US9745368B2 (en) 2013-03-15 2017-08-29 The Trustees Of The University Of Pennsylvania Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
AR095374A1 (en) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Binding molecules for bcma and cd3
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
UY35468A (en) 2013-03-16 2014-10-31 Novartis Ag Cancer treatment using a chimeric receptor antigen anti-CD19
CN106459989A (en) 2013-12-19 2017-02-22 诺华股份有限公司 Human mesothelin chimeric antigen receptors and uses thereof
EP3114217A4 (en) * 2014-03-07 2017-09-20 Bellicum Pharmaceuticals, Inc. Caspase polypeptides having modified activity and uses thereof
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
CA2984484A1 (en) * 2014-05-02 2015-11-05 The Trustees Of The University Of Pennsylvania Compositions and methods of chimeric autoantibody receptor t cells
BR112017001242A2 (en) 2014-07-21 2017-12-05 Novartis Ag treatment of cancer using a chimeric receptor antigen CD33
US20160051651A1 (en) 2014-07-21 2016-02-25 The Trustees Of The University Of Pennsylvania Treatment of cancer using a cll-1 chimeric antigen receptor
JP2017527271A (en) 2014-07-21 2017-09-21 ノバルティス アーゲー Treatment of cancer using human anti bcma chimeric antigen receptor
RU2017106025A3 (en) 2014-07-24 2019-02-15
CA2958553A1 (en) 2014-08-19 2016-02-25 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
RU2017134652A (en) 2015-04-08 2019-04-09 Новартис Аг Cd20 therapy, CD22 therapy, and combination therapy with cells expressing the chimeric antigen receptor (car) k cd19
EP3331905A1 (en) * 2015-08-06 2018-06-13 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
KR20180042361A (en) * 2015-08-24 2018-04-25 셀렉티스 The chimeric antigen receptor with the integrated control features available

Also Published As

Publication number Publication date
WO2017181119A2 (en) 2017-10-19
IL262321D0 (en) 2018-11-29
WO2017181119A3 (en) 2018-01-04
EP3443096A2 (en) 2019-02-20
AU2017250304A1 (en) 2018-11-08
JP2019518424A (en) 2019-07-04
KR20180134385A (en) 2018-12-18
CN109715808A (en) 2019-05-03
BR112018071096A2 (en) 2019-02-26
CA3021027A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
SG11201407802WA (en) Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
SG11201407793TA (en) Compounds and compositions for modulating egfr activity
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201407900WA (en) Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
SG11201408124PA (en) Differentiation of human embryonic stem cells into pancreatic endocrine cells
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201808076UA (en) Facilitating vehicle driving and self-driving
SG11201807002TA (en) Intention signaling for an autonomous vehicle
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport
SG11201407644UA (en) Methods for making fully human bispecific antibodies using a common light chain
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201407819UA (en) Improved methods of cell culture for adoptive cell therapy
SG11201408769QA (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201408153YA (en) Prostate-specific membrane antigen antibody drug conjugates
SG11201807771UA (en) Multiple dispersion generator e-vaping device
SG11201408347UA (en) Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
SG11201406977TA (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
SG11201407483YA (en) Compositions and methods for modulating smn gene family expression
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201408261UA (en) Syringe
SG11201804839WA (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
SG11201407710VA (en) Compositions comprising short-acting benzodiazepines
SG11201806340YA (en) Zika virus vaccine
SG11201407265RA (en) Novel ha binding agents
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins